‘BOOSTING VACCINE MANUFACTURING FOR EXPORTS’

“We already have expressions of interest for the ZyCoV-D vaccine from many countries. Obviously, the first phase for us till we scale up to very large quantities is to supply to the Indian immunisation programme and once that is sufficiently catered to, we will also get export permission for the vaccine. We are looking at partnering with one CMO outside India who also has drug substance manufacturing capabilities. That will further boost our manufacturing and supply for international markets. We have already developed the DNA vaccine candidates for the Alpha, Beta, Kappa Delta, Delta Plus and Lambda variants and established process for the same as well in a very short period of time, which will provide a flexibility in programmatic implementation to switch to newer vaccine candidates based on new variants and thereby ensuring faster control over the pandemic.”

- DR SHARVIL PATEL, Managing Director, Cadila Healthcare, India